

Magistral Phage Therapy

Personalized Precision Solutions Against Bacterial Infections (including AMR)

We provide personalized precision bacteriophage solutions for the treatment of complex and difficult-to-treat bacterial infections, including those caused by antimicrobial-resistant (AMR) pathogens. Our approach enables personalized, patient-specific therapy when conventional antibiotics are ineffective or insufficient.

Key Features

- **Targeted phage preparations**
Pre-prepared or custom-made bacteriophage formulations tailored to the patient's clinical isolate.
- **Therapeutic alternative or adjunct to antibiotics**
Can be used alongside antibiotics or as a standalone treatment option.
- **Individualized therapeutic approach**
Developed in accordance with magistral (pharmacy compounding) preparation principles.

Clinical Workflow

1. Clinical sample collection
2. Phage matching and susceptibility testing
3. Selection of JAFRAL's GMP-grade phage API
4. Drug product preparation and compounding
5. Patient-specific treatment administration

Regulatory Framework

- Prepared under magistral and pharmacy compounding frameworks.
- Intended for individualized therapeutic use.
- Sterile formulations, including products suitable for intravenous (IV) administration.

Currently Available Phage Products

JAFPA

Bacteriophages targeting *Pseudomonas aeruginosa*

JAFSA

Bacteriophages targeting *Staphylococcus aureus*



Products in Development

Phage preparations targeting:

- *Escherichia coli*
- *Staphylococcus epidermidis*
- *Klebsiella pneumoniae*
- *Acinetobacter baumannii*
- *Enterococcus faecalis*
- *Clostridioides difficile*
- *Cutibacterium acnes*
- Additional clinically relevant bacterial species

Routes of Administration

- Topical
- Inhaled
- Intravesical
- Intravenous (IV)

Deliverables

- Sterile GMP-grade Active Pharmaceutical Ingredient (API)
Supplied in crimped glass vials
- Certificate of Analysis (CoA)
Provided with each batch

Clinical Relevance

Our phage-based solutions are designed for the treatment of chronic, recurrent, or antibiotic-resistant infections, including:

1. Pulmonary Infections

- Cystic fibrosis (CF)
- Non-CF bronchiectasis
- Ventilator-associated pneumonia (VAP)

2. Skin, Wound, and Burn Infections

- Chronic wound infections
- Diabetic foot infections
- Burn wound infections
- Surgical site infections

3. Bone, Joint, and Implant-Associated Infections

- Osteomyelitis
- Prosthetic joint infections (PJI)
- Fracture fixation hardware infections

4. Cardiovascular and Device-Related Infections

- LVAD (left ventricular assist device) infections
- Vascular graft infections
- Central line-associated infections

5. Urinary Tract Infections (UTIs)

- Complicated and recurrent UTIs

6. Bloodstream and Systemic Infections (experimental use)

- Bacteraemia and sepsis (last-resort, salvage therapy only)

7. Additional Indications

- Skin and soft tissue infections (SSTI)
- Endocarditis (selected salvage cases)

If you would like to learn more about our personalized bacteriophage solutions, please contact us at info@jafRAL.com

Physicians and pharmacists interested in clinical use are invited to reach out to us directly to discuss potential collaboration.